Analyse von Tiermodellen der chronischen Herzinsuffizienz basierend auf der Kombination der Krankheitssyndrome der chinesischen und westlichen Medizin

  • role: First author第一作者
  • Affiliation:

    Liaoning University of Chinese Medicine,Shenyang 110000,China

  • Email:121000362@qq.com
  • Introduction:张雪妍,在读博士,从事中西医结合防治心血管疾病研究,E-mail:121000362@qq.com
ZHANG Xueyan1,  
  • Affiliation:

    Liaoning University of Chinese Medicine,Shenyang 110000,China

ZHANG Kexin1,  
  • Affiliation:

    The Second Affiliated Hospital of Liaoning University of Chinese Medicine,Shenyang 110000,China

YU You2,  
  • Affiliation:

    Liaoning University of Chinese Medicine,Shenyang 110000,China

ZHANG Huan1,  
  • Affiliation:

    Liaoning University of Chinese Medicine,Shenyang 110000,China

DUAN Yingzhu1,  
  • role: Corresponding author通信作者
  • Affiliation:

    Liaoning University of Chinese Medicine,Shenyang 110000,China

  • Email:yurui1969@163.com
  • Introduction:于睿,教授,博士生导师,从事中西医结合防治心血管疾病研究,E-mail:yurui1969@163.com
YU Rui1*

Resümee

Chronische Herzinsuffizienz (CHI) ist das Endstadium von Herz-Kreislauf-Erkrankungen, dessen Prävalenz in unserem Land hoch bleibt. Diese Studie recherchierte und klassifizierte vorhandene Daten zu CHI-Tiermodellen und bewertete die klinische Übereinstimmung der einzelnen Modelle unter Berücksichtigung der klinischen Syndrome der traditionellen chinesischen und westlichen Medizin sowie deren Vor- und Nachteile. Die Modelle mit hoher Übereinstimmung in der traditionellen chinesischen Medizin sind das Adriamycin-Modell, das Isoprenalin-Modell und das Ligation-des-Liganden-Modell der linken vorderen absteigenden Koronararterie, bei denen die Übereinstimmung mit der chinesischen Medizin jeweils 90 % beträgt. Das Modell mit der höchsten Übereinstimmung mit der westlichen Medizin ist das Ligation-Modell der linken vorderen absteigenden Koronararterie mit einer Übereinstimmung von 82 %. Jedes Modell hat seine Vor- und Nachteile, die meist darin liegen, dass es an Modellierungsmethoden fehlt, die Syndrome der chinesischen und westlichen Medizin kombinieren. Die aktuellen Tiermodelle werden hauptsächlich durch einen einzelnen Auslöser erzeugt und spiegeln hauptsächlich die Ätiologie und Pathogenese der westlichen Medizin wider, während die Verbindung zur Pathogenese der traditionellen chinesischen Medizin gering ist und die typischen Syndrommerkmale der chinesischen Medizin nicht ausreichend dargestellt werden, was zu einer insgesamt niedrigen Übereinstimmung zwischen chinesischer und westlicher Medizin führt. Die chinesische Medizin bietet den Vorteil einer multidimensionalen Differenzialdiagnose und Behandlung. Es sollte eine Kombination der Syndromeigenschaften der chinesischen und westlichen Medizin erfolgen, multifaktorielle Modellierungsmethoden angewandt werden, die den pathologischen Prozess der CHI gemeinsam widerspiegeln, bestehende Modelle verbessert und Tiermodelle entwickelt werden, die besser den klinischen Syndrommerkmalen der chinesischen und westlichen Medizin entsprechen, um eine zuverlässige Grundlage für Prävention und Therapie in der Klinik zu bieten.

Schlüsselwort

chronische Herzinsuffizienz;Tiermodelle;Integration von Krankheitssyndromen;chinesische und westliche Medizin

References

  1. 1.
    National Center for Cardiovascular Diseases,The Writing Committee of the Report on Cardiovascular Health and Diseases in China.Report on cardiovascular health and diseases in China 2023:An updated summary[J].Chin Circ J,2024,39(7):625-660.
  2. 2.
    LAN C,SU W B,YAN X D,et al.Recent advances of clinical researches on drug therapy for chronic heart failure[J].Chin J Hosp Pharm,2024,44(12):1467-1471.
  3. 3.
    FENG S,BAI C C.Research progress of integrated traditional Chinese and western medicine in treating chronic heart failure[J].J Pract Tradit Chin Int Med,2023,37(4):140-142.
  4. 4.
    HE Y F,ZHU H Y,ZHANG Y H,et al.Research progress of traditional Chinese and western medicine modeling methods in small animal models of chronic heart failure[J].World Chin Med,2024,19(16):2508-2513.
  5. 5.
    LIAN K,LI X,HU S Y,et al.Visual analysis of research trends and hotspots in animal models of chronic heart failure[J].Tradit Chin Drug Res Clin Pharmacol,2024,35(3):394-401.
  6. 6.
    CHEN J B,QIN G F,ZHAO G.Advances in pathogenesis and treatment of chronic heart failure in traditional Chinese and western medicine[J].Chin J Integr Med Cardio-Cerebrovasc Dis,2019,17(3):378-380.
  7. 7.
    PENG L Q,DENG X,CAI H Z,et al.TCM understanding and prevention of chronic heart failure:Research on CHEN Xinyu's academic thought and clinical experience[J].J Hunan Univ Chin Med,2021,41(10):1615-1619.
  8. 8.
    YU Y J,ZHOU Z Y,JIN X Y,et al.Professor ZHANG Boli's experience in the treatment of chronic heart failure[J].Tianjin J Tradit Chin Med,2024,41(1):6-8.
  9. 9.
    LIU W Y,QU H Y,WANG T,et al.Professor Zhou Hua's experience summary in treating heart failure based on the pathogenesis theory of "Yang weakness and Yin exuberance"[J].China Medical Herald,2022,19(9):132-135.
  10. 10.
    Cardiovascular Branch of Chinese Medical Association, Cardiovascular Physicians Branch of Chinese Medical Doctor Association, Heart Failure Professional Committee of Chinese Medical Doctor Association, et al.Chinese guidelines for the diagnosis and treatment of heart failure 2024[J].Chin J Cardiol,2024,52(3):235-275.
  11. 11.
    HEIDENREICH P A,BOZKURT B,AGUILAR D,et al.2022 AHA/ACC/HFSA guideline for the management of heart failure:A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines[J].Circulation,2022,145(18):e895-e1032.
  12. 12.
    TIAN S,CAO L H,MIAO M S,et al.A new method for the evaluation of animal models used in traditional Chinese Medicine based on the clinical characteristics of Chinese and Western medicine[J].Pharmacol Clin Chin Mater Med,2017,33(6):165-169.
  13. 13.
    Project Group of Traditional Chinese Medicine Guideline for Diagnosis and Treatment of Chronic Heart Failure,China Association of Chinese Medicine.Traditional Chinese medicine guideline for diagnosis and treatment of chronic heart failure(2022)[J].J Tradit Chin Med,2023,64(7):743-756.
  14. 14.
    CHEN H,ZHENG L M,GUO Y S,et al.Experts consensus on commonly used experimental mice and rats models of cardiovascular diseases[J].Chin J Hypertension,2022,30(8):710-719.
  15. 15.
    HOU W F,ZHANG M S,ZHANG L,et al.Research progress using animal models of vascular cognitive impairment[J].Acta Lab Anim Sci Sin,2021,29(4):542-552.
  16. 16.
    ZHANG Q,WEI X H,CHEN J,et al.Advances in animal models of chronic heart failure and its applications in traditional Chinese medicine[J].China J Chin Mater Med,2023,48(3):614-624.
  17. 17.
    LI D Y,FAN L,HE K L,et al.Improved left ventricular function in chronic heart failure dogs by skeletal autologous myoblast transplantation[J].Chin Circ J,2009,24(6):468-471.
  18. 18.
    DIGUET N,TRAMMELL S,TANNOUS C,et al.Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy[J].Circulation,2018,137(21):2256-2273.
  19. 19.
    ZHAO J.Experimental study of Sini decoction on myocardial apoptosis in TAC-induced chronic heart failure mice[D].Beijing:Beijing University of Chinese Medicine,2019.
  20. 20.
    ZHONG S J,XIONG X J,ZHANG Q,et al.Pathological process observation and non-targeted metabolomics analysis of heart failure rat model established by transverse aortic constriction[J].Chin J Exp Tradit Med Form,2022,28(9):117-124.
  21. 21.
    LIU P,PAN Q.Butein inhibits oxidative stress injury in rats with chronic heart failure via ERK/Nrf2 signaling[J].Cardiovasc Ther,2022,2022:8684014.
  22. 22.
    XU P,XU H S,CHEN J,et al.Establishment and evaluation of chronic heart failure rats with heart Yang deficiency[J].Chin Arch Tradit Chin Med,2016,34(8):1957-1960.
  23. 23.
    WANG R,YAN X M,WANG Y,et al.Effect of Fuzi decoction based on chronic heart failure rats model and its mechanism[J].Chin Arch Tradit Chin Med,2019,37(4):788-792,1026.
  24. 24.
    ZOU S F.The role and mechanism of KLF15 in inhibiting heart failure caused by ventricular overload in mice[D].Chongqing:Chinese People's Liberation Army Army Medical University,2019.
  25. 25.
    CHEN X F.Effect and mechanism of daaglipzin,a sodium-glucose cotransporter 2 inhibitor,on cardiac function in non-diabetic rabbits with chronic heart failure[D].Shijiazhuang:Hebei medical university,2023.
  26. 26.
    ZHOU H.Effect and mechanism of Qiliqiangxin capsule on ventricular remodeling in mice after relieving high pressure load[D].Shenyang:Liaoning University of Traditional Chinese Medicine,2023.
  27. 27.
    POPEVSKA S,RADEMAKERS F.The left ventricular pressure-volume area and stroke work in porcine model of ascending compared to descending thoracic aorta stenosis creating a chronic early vs.late left ventricular afterload increase[J].Pril(Makedon Akad Nauk Umet Odd Med Nauki),2022,43(2):111-121.
  28. 28.
    SHEN M J.Study on the improvement of right ventricular remodeling in mice after pulmonary artery constriction with sacubactril/valsartan[D].Guangzhou:Southern Medical University,2021.
  29. 29.
    WANG S B.Construction of pulmonary artery constriction model and right heart remodeling in Suckling rats[D].Shanghai:Shanghai Jiao Tong University,2017.
  30. 30.
    ZHANG J B,NIU X L,LU Y,et al.Effects of bisoprolol on HCN channel mRNA expression and intrinsic heart rate in sinoatrial node of rats with aorta level left-to-right shunt[J].J Xi'an Jiaotong Univ(Med Sci),2013,34(2):189-193,213.
  31. 31.
    HAN K,WU G R,XI Y T,et al.Establishment of rat model of volume-overloaded heart failure and reviewing on heart function by echocardiography[J].Chin J Evid-Bas Cardiovasc Med,2013,5(5):507-509.
  32. 32.
    DONG X L,YUAN B H,YU S Z,et al.Adriamycin induces cardiac fibrosis in mice via PRMT5-mediated cardiac fibroblast activation[J].Acta Pharmacol Sin,2023,44(3):573-583.
  33. 33.
    LI L J,MA X T,HUANG J,et al.Establishment and evaluation of chronic heart failure rat model with Xinshenyangxu(心肾阳虚) syndrome[J].Pharmacol Clin Chin Mater Med,2022,38(2):217-222.
  34. 34.
    LIN J M,GUO W X,WANG Y,et al.Establishment of chronic heart failure rat model of Xin-Qi deficiency complicated blood stasis and edema syndrome and judgment of diagnosis information integration[J].Chin J Integr Tradit West Med,2014,34(12):1457-1462.
  35. 35.
    YU Y B,LIANG H,DONG W B,et al.Pathological differences and Chinese medicine pattern evaluation of three rat models of heart failure[J].J Hunan Univ Chin Med,2024,44(5):737-743.
  36. 36.
    WEI J M,LIU C X,LI H,et al.Therapeutic effect and mechanism of the effective componets of Yixintai in chronic heart failure rabbits with heart-Qi deficiency complicated blood stasis and edema syndrome[J].China Arch Tradit Chin Med,2023,38(12):5748-5753.
  37. 37.
    LI X H,WANG Y J,ZHANG G L,et al.Preventive and therapeutic effect of Qili Qiangxin capsule on daunorubicin cardiotoxicity[J].J Liaoning Univ Tradit Chin Med,2017,19(6):27-30.
  38. 38.
    FANG Q J,LIAN J B,WU Z J,et al.Establishment and evaluation of chronic heart failure model in young rats induced by daunorubicin[J].Chin J App Physiol,2013,29(2):113-115,195.
  39. 39.
    GAO L,LI T,LI S,et al.Schisandrin A protects against isoproterenol‑induced chronic heart failure via miR‑155[J].Mol Med Rep,2022,25(1):24.
  40. 40.
    BI J B,LI T.Telmisartan inhibits NLRP3/GSDMD/Caspase-1 signaling pathway to improve cardiac function in chronic heart failure rats[J].Prog Anat Sci,2024,30(3):255-258.
  41. 41.
    HUANG S M,LIAO X Q,FAN X Y,et al.Preparation of a rat model of chronic heart failure induced by isoprenaline based on "inferring pattern by the formula" and its pattern types[J].J Hunan Univ Chin Med,2023,43(3):368-375.
  42. 42.
    YU Y P,LIANG H,DONG W B,et al.Pathological differences and Chinese medicine pattern evaluation of three rat models of heart failure[J].J Hunan Univ Chin Med,2024,44(5):737-743.
  43. 43.
    YANG M,HU S Y,LI L,et al.Chinese medical syndrome and nature of isoproterenol-induced chronic heart failure mice based on syndrome determination by formulas[J].Pharmacol Clin Chin Mater Med,2024,40(2):101-108.
  44. 44.
    SHARMA N M,LLEWELLYN T L,ZHENG H,et al.Angiotensin Ⅱ-mediated posttranslational modification of nNOS in the PVN of rats with CHF:Role for PIN[J].Am J Physiol Heart Circ Physiol,2013,305(6):H843-855.
  45. 45.
    WANG Y.The role and mechanism of interleukin-38 in chronic heart failure[D].Wuhan:Huazhong University of Science and Technology,2023.
  46. 46.
    ZHANG Y J.Study on the mechanism of Qiliqiangxin capsule in treating chronic heart failure based on network pharmacology[D].Liaoning Univ Chin Med,2021.
  47. 47.
    HU L,XU Y N,WANG Q,et al.Aerobic exercise improves cardiac function in rats with chronic heart failure through inhibition of the long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1(MALAT1)[J].Ann Transl Med,2021,9(4):340.
  48. 48.
    YU Z J,ZHANG G J,CHEN L X,et al.Effects of apigenin regulating caveolin-1 on angiotensin 1-7 and left ventricular diastolic function in rats with chronic heart failure[J].Chin J Integr Med Cardio-Cerebrovasc Dis,2024,22(9):1591-1596.
  49. 49.
    FENG X C,GUO S Z,WU Z Q,et al.Evaluation of relevant information in chronic heart failure rats in Qi deficiency and blood stasis syndrome[J].China J Tradit Chin Med Pharm,2014,29(5):1563-1567.
  50. 50.
    GUAN Z J,CHEN Z X,JIANG J L,et al.Effect of Nuanxinkang on improving cardiac function in mice with heart failure by inhibiting endoplasmic reticulum stress[J].China J Tradit Chin Med Pharm,2022,37(11):6791-6795.
  51. 51.
    REN J X,YIN C Y,SHI Y H,et al.Evaluation on sleep deprivation combined with left anterior descending coronary artery ligation to establish rat model of heart failure with Qi deficiency and blood stasis syndrome[J].J Tradit Chin Med,2020,61(5):428-434.
  52. 52.
    ZHANG W.Study on mechanism of Bushen Huoxue compound in intervening myocardial fibrosis of chronic heart failure after myocardial infarction based on Wnt/β-catenin pathway[D].Shenyang:Liaoning University of Chinese Medicine,2021.
  53. 53.
    URBAN J F,GERHART R L,KRZESZAK J R,et al.Methods for the development and assessment of atrial fibrillation and heart failure dog models[J].J Geriatr Cardiol,2011,8(3):133-140.
  54. 54.
    LI D Y,FAN L,HE K L,et al.Autologous skeletal myoblast transplantation improves hemodynamics dogs with chronic heart failure dogs[J].J South Medl Univ,2010,30(3):475-477.
  55. 55.
    LI T.Study on the mechanism of LncRNAGAS5 targeting miR-223-3p/NLRP3 axis in regulating myocardial injury caused by coronary microembolization[D].Nanning:Guangxi Medical University,2022.
  56. 56.
    CAO Q.Effect of electrical stimulation of carotid sinus baroreceptor on chronic heart failure in dogs[D].Wuhan:Wuhan University,2018.
  57. 57.
    LIANG X Y.Intervention of PI3k/Akt/mTOR pathway to regulate Tregs/Th17 immune homeostasis and its mechanism on ventricular remodeling in heart failure[D].Urumqi:Xinjiang Medical University,2022.
  58. 58.
    NOSZCZYK-NOWAK A,PASłAWSKA U,GAJEK J,et al.Ventricular effective refraction period and ventricular repolarization analysis in experimental tachycardiomyopathy in swine[J].Adv Clin Exp Med,2016,25(3):409-414.
  59. 59.
    ADAMS V,ALVES M,FISCHER T,et al.High-intensity interval training attenuates endothelial dysfunction in a Dahl salt-sensitive rat model of heart failure with preserved ejection fraction[J].J Appl Physiol,2015,119(6):745-752.
  60. 60.
    ZHOU Y.Study on the mechanism of myocardial fibrosis in hypertensive heart failure based on TGF-β/Smad pathway and intervention with "prescription test"[D].Changsha:Hunan University of Chinese Medicine,2019.
  61. 61.
    CAO H J.Role of immune proteasome β5i subunit in deoxycorticosterone acetate(DOCA) -salt induced cardiac remodeling and its molecular mechanism[D].Dalian:Dalian Medical University,2019.
  62. 62.
    HAO J M.The effect and mechanism of Qiliqiangxin capsule on heart failure with preserved ejection fraction guided by meridian theory[D].Shijiazhuang:Hebei Medical University,2022.
  63. 63.
    HOJNÁ S,MALÍNSKÁ H,HÜTTL M,et al.Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet[J].Biomed Pharmacother,2024,174:116520.
  64. 64.
    LIAO Y Q,FENG J Y,LI Z H,et al.Role of short-chain acyl-CoA dehydrogenase in chronic heart failure of elderly spontaneously hypertensive rats[J].J Guangdong Pharm Univ,2019,35(3):412-417.
  65. 65.
    DONG F.Effect of QishenLiuwei decoction on myocardial fibrosis in spontaneously hypertensive rats[D].Beijing:Beijing University of Chinese Medicine,2021.
  66. 66.
    KUANG H Y.BCAA/mTORC1 mediates left ventricular remodeling in spontaneously hypertensive rats[D].Chongqing:Chongqing Medical University,2023.
  67. 67.
    LI C G.Study on the mechanism of englazine on myocardial oxidative stress and fibrosis in diabetic patients[D].Tianjin:Tianjin Medical University,2019.
  68. 68.
    HE Y T,TANG L P,ZHANG B X.Advances in rat models of heart failure[J].Cardiovas Dis Elec J Integrated Tradit Chin West Med,2015,3(18):190-191.
  69. 69.
    ZHANG W.Study on mechanism of Bushen Huoxue compound in intervening myocardial fibrosis of chronic heart failure after myocardial infarction based on Wnt/β-catenin pathway[D].Shenyang:Liaoning University of Traditional Chinese Medicine,2022.
  70. 70.
    ZHANG Q L,ZHANG Y P,ZHOU Z D,et al.Construction of a mouse model of adriamycin-induced cardiomyopath[J].China Oncol,2022,32(10):948-959.
  71. 71.
    XIA R,ZHU G Q,GAO B,et al.Doxorubicin induces chronic heart failure in rats by regulating mitochondrial dynamics via DRP1/FUNDC1 pathway[J].Chin Pharmacol Bull,2022,38(11):1661-1666.
  72. 72.
    ZHANG Y X,JI F L,WANG X,et al.Study on the model of chronic heart failure induced by adriamycin in rats[J].Chin J Gerontol,2021,41(12):2576-2581.
  73. 73.
    LI X X.Study on the clinical effect of Qishentaohong Granules in treating chronic heart failure and the mechanism of immune regulation[D].Beijing:Beijing University of Chinese Medicine,2023.

Lesen Sie die ganze Passage

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website